Marinus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Marinus Pharmaceuticals has a total shareholder equity of $16.8M and total debt of $109.0M, which brings its debt-to-equity ratio to 649.9%. Its total assets and total liabilities are $170.9M and $154.1M respectively.
Key information
649.9%
Debt to equity ratio
US$108.95m
Debt
Interest coverage ratio | n/a |
Cash | US$150.29m |
Equity | US$16.77m |
Total liabilities | US$154.14m |
Total assets | US$170.91m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0JYL's short term assets ($165.2M) exceed its short term liabilities ($40.6M).
Long Term Liabilities: 0JYL's short term assets ($165.2M) exceed its long term liabilities ($113.5M).
Debt to Equity History and Analysis
Debt Level: 0JYL has more cash than its total debt.
Reducing Debt: 0JYL's debt to equity ratio has increased from 0% to 649.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0JYL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 0JYL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.